...continued from above:
As I am a very subjective person, I feel it wouldn't be right if I didn't bring up the contrary. On the flip side, this could be another manipulation by Zami. He's feeling the pressure to add shareholder value. He knows the ATM was holding things back & maybe the dissolution was just that, with no further meaning.
Perhaps he knows his job is on the line. The guy has proven himself to be a little shady and less than communicative. I have neither trust nor confidence in him. The contract was terminated in September, after the close of the quarter ending June 30, 2014. They still had 2+ months to put more shares on the market without needing to report them on this 10-K. This is doubtful, though, as the volume has been relatively low.
With trial results on the horizon, I tend to hope for the former. The company is approaching a critical phase in their development. I believe investors are holding back for something a little more concrete than the hype of pre-clinicals and possibilities. The full data set for the hip replacement trial is not that far off. It's make or break time. The next six months are pivotal.
Good luck everyone.
Disclosure: These are purely speculative posts.
There's a lot to be said of this termination. To say it backfired, I don't think is a realistic conclusion. The stock price is only relevant as it pertains to the number of shares to be issued to achieve a certain monetary goal. I've been giving this some thought and I believe there may be something beyond this.
The first thing that popped into my head was a partnership. Upon further reflection, though, I don't feel any partner really cares about dilution. Their goal is to bring the licensed product to market & how PSTI stands in the eyes of investors has no bearing. So, why would they care about an ATM or the stock price? In reality, they would want their investment to have cash at the helm to validate their faith in said partner, PSTI.
Now, who does care about dilution? Investors. Perhaps someone is finally interested in dropping some cash. As a tiny retail investor, this ATM was a burden. To a large institution, it appears even bigger. I despised the fact they could dilute at the drop of a dime. If I owned, or would consider owning, 5+%, it would disgust me even further. I would demand the contract be terminated & insist any further dilution occur via a secondary offering, at my discretion. I would want value for my investment.
Hence, my humble conclusion is that some parties have displayed a consideration in the technology. In order for them to commit, Zami would need to pledge a temporary stoppage to any further issuance of shares, in other words, terminate the ATM. It would be in their best interest. Like it or not, these large stakeholders have a lot of influence in the operational aspects of a company.
As it appears on the surface, this would be my best guess. Let's hope it's true & it's with an American firm.
He doesn't flag posts, he only removes his posts that users have replied to which speak the truth or call him out. As a result, those replies also get removed from the thread but stay on the message list. Don't let him get under your skin. I'm telling you, I laugh at almost every post he makes. These guys have zero credibility with me and I'm sure with many others as well. It would be a relief to see him disappear along with his alter egos placenta power and buteo.
And yes buteo is allo ! Look at some of his earlier posts ! Same grammar and sentence structure !
I guess no report of earnings today either? Maybe they don't want to reveal the many millions of shares that were issued last quarter.
Zami releases the day before earnings? I will give him credit for the update, but talk about a feeble attempt at pumping the company. Wow, 3 patients were dosed...
We definitely saw a nice bounce from the 2.58 low with a couple good volume days. I wouldn't be surprised if that was the bottom, barring any negative news. The six month sell off was pretty dramatic in that there really weren't many support levels to judge by. It seemed to just tumble past any given level. The technicals definitely favor a turn for the better. There will be some resistance at 3, especially with earnings coming out this week. If we can roll past that, then I still believe there are many levels to bust through, 3.11, 3.17, 3.25, 3.34, 3.50, barring any positive news. If we do hit the 3.69 level, then I don't see much resistance back up to 4. I still think it will be a while before we see significant upsides, though. The 2 current trials aren't due to complete until early next year and trial initiations aren't typically catalysts for the long term.
The near term make or break play is the hip replacement trial. The final data set will tell the story. Unfortunately, they're holding back for some reason or maybe it's just not ready. Either way, they promised us details this year and so far, no word. This would be the best shot for any partnership.
Bottom line, results are what we need. Let's hope they're good.
Thanks for your support caltrial, but as you can see, allo knows the truth and can't answer a single question I have posted here. Instead, he and his multiple pseudonyms have taken to the nonsensical tactic of removing posts which have replies opposing their own, thus removing any subsequent posts in that thread. My advice to all is to not reply directly to allo but rather start a new topic or reply directly to the author. This allo group has become very infantile, they behave like 2 year olds at times.
Why these presentations are not simulcast? Where is the complete data set from the hip replacement trial that was promised to be presented at a medical conference? Though not SAE's, what were the adverse events that were resolved during this trial? Why is there NEVER a conference call to discuss earnings and the progression of the company? Why did Zami lie about the 2 deaths, saying he didn't know, yet nonchalantly mentioned the second death in his statement to a newspaper? Why are investors left in the dark? Why are the institutions shying away from this company? Why were there 3.6M "nay" votes for Zami retaining his position? These are questions we can't answer but are legitimate in asking.
I'm watching this level carefully myself. Support seems to be developing here but I will still wait until I see the 10-Q next week.
...and they won't be attending the Alliance for Regenerative Medicine "Stem Cell Meeting on the Mesa" Conference next month.
...and why is Zami not involved in this workshop, his area of "expertise"?
7:30am MANUFACTURING & SCALE-UP WORKSHOP
Chair: Robert Preti, Ph.D., Co-Founder & President, Progenitor Cell Therapy (PCT); Chief Scientific Officer, NeoStem
Stewart Abbot, Ph.D., Executive Director, Integrative Research, Celgene Cellular Therapeutics
Ian Harris, Ph.D., Senior Director, Janssen R&D
Stephen Ward, Ph.D., Chief Operating Officer, Cell Therapy Catapult
to speak to the general investment community? Every other attendee at the Rodman & Renshaw Conference next week will be simulcasting their presentation live, but once again, Pluistem won't. Can anyone explain why? And with earnings next week, where's the conference call? Seriously, this guy is a joke.
I did realize that the first paragraph wasn't really indicative of my style and probably should not have been made the introduction, and for that I apologize, but my point remains the same. I don't believe he is the one to take this company where it needs to be. Period.
....alpo, what was the rumor we are all missing??.....
Zami , The Egocentric Engineer
His focus is on everything but the actual product, typical cart before the horse. We hear more of his engineering feats & very little about the therapeutic effects everyone is waiting for. He can't pitch the company, is a horrible public speaker, is deceitful & has become more of a liability. What makes you guys think an engineer & a CPA can run a Medical Company? Zami & His Lackey Yaky.
A measly $3M of the billions available to these guys. This is good news? There are a few new names, but only nickels invested. Still waiting for some stakeholders.
So, Big Pharma has skipped right over PSTI (again). Why? People say Zami won't sell, which is fine, but where's the partnering deal? Zami has been talking partners for years now.
Where's the complete data set from the hip replacement trial? Zami said this would be presented at a medical conference this year. One of the biggest happens in California in early October & we aren't there. Today is the deadline for presenters.
Honestly, I would also think PSTI has some data in their hands from the IC trial. I don't know for sure, but it makes sense this data was turned over to the company after the halt so they could better analyze the cause & give a response. More secrets?
These are moving along, sloowwwlly.
I've been saying this for a few quarters now. Every 10Q is a #$%$ shoot as to how many shares were issued. Cashless warrants, deeply discounted warrants, the ATM, etc. We see in two weeks. Any guesses?
I thought about jumping back on board with these depressed prices, but I don't see any momentum bringing it back up. Until I see a some solid upticks, I'm holding off. Definitely not before the 10Q at this point.
Take these thoughts for what you will. Good luck.
Unfortunately, I can't really begin to translate this. It seems they often present more about the manufacturing techniques and report less heavily on the therapeutics.